Dr. Mark Armando Prendes, MD

Dr. Prendes practices at Cleveland Eye and Laser Surgery Center in Fairview Park, Ohio.

Dr. Prendes' NPI, 1073874954, was assigned on June 6, 2012. Dr. Prendes graduated from Indiana University School of Medicine in 2012. Dr. Prendes holds Ohio license 35.133570.

Dr. Prendes' primary practice is Cleveland Eye and Laser Surgery Center, at 22715 Fairview Center Drive, Fairview Park, OH 44126. The practice phone is (216) 777-8400. Dr. Prendes also practices at Cleveland Eye and Laser Surgery Center LLC, 22710 Fairview Center Dr, Cleveland, OH 44126.

Dr. Prendes' primary practice is Cleveland Eye and Laser Surgery Center in Fairview Park, Ohio. Dr. Prendes is also affiliated with University Hospitals TriPoint Medical Center. The medical group on file is University Hospitals Medical Practices. Dmand AI also links Dr. Prendes to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Prendes practices, 8 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Prendes' primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Prendes is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Prendes is licensed in Ohio.

CMS data shows 839 Medicare services from Dr. Prendes across 18 procedure codes in 2024, for 403 Medicare patients. Medicare paid $143,118 for them.

CMS counts 403 Medicare patients who saw Dr. Prendes in 2024. The largest group is 65 to 74, with 223 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 3% are also on Medicaid. Their average risk score is 1.06, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Prendes' median patient age at 70, with 66% women.

In 2024, Dr. Prendes wrote 341 Medicare Part D claims for 225 patients. 92% of them were for generic drugs. CMS names the drug for 283 of them, across 4 drugs with 11 or more claims each, at $2,594 in total drug cost. In 2023, CMS named 72 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Prendes for performance year 2024, reported as part of a group. Dr. Prendes accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 20 papers to Dr. Prendes, published from 2013 to 2023. 2019 was the busiest year, with 3. The most frequent topics are Orbit, Ophthalmologic Surgical Procedures and Postoperative Complications. Dr. Prendes has published most often in Ophthalmic Plast Reconstr Surg. Dr. Prendes' most frequent co-authors are William R. Nunery, MD, Jeremy Dustin Clark, MD and Lilangi Ediriwickrema, MD.

CMS Open Payments shows 62 general payments to Dr. Prendes from 17 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 82% of the total. Medical Device Business Services, Inc. paid the most, $7,917.

Dr. Prendes graduated from Indiana University School of Medicine in 2012.